


PRODUCT INFORMATION



Olomoucine

Item No. 10010240

CAS Registry No.: 101622-51-9
Formal Name: 2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-ethanol
MF: C₁₅H₁₈N₆O
FW: 298.3
Purity: ≥98%
UV/Vis.: λ_{max}: 231, 290 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Olomoucine is supplied as a crystalline solid. A stock solution may be made by dissolving the olomoucine in the solvent of choice, which should be purged with an inert gas. Olomoucine is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of olomoucine in these solvents is approximately 10, 20, and 30 mg/ml, respectively.

Olomoucine is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, olomoucine should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Olomoucine has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. Olomoucine is a CDK inhibitor that acts by competing for the ATP binding site of the kinase. This purine derivative is an inhibitor for CDC2/cyclin B (IC₅₀ = 7 μM), Cdk2/cyclin A (IC₅₀ = 7 μM), Cdk2/cyclin E (IC₅₀ = 7 μM), CDK/p35 kinase (IC₅₀ = 3 μM), and ERK1/p44 MAP kinase (IC₅₀ = 25 μM).¹ Olomoucine inhibits DNA synthesis in interleukin-2 stimulated T lymphocytes, triggers G₁ arrest, and is also used to synchronize cells in G₁.¹ This inhibitor can attenuate astroglial proliferation and glial scar formation, decrease lesion cavity and mitigate functional deficits after spinal cord injury (SCI) in rats.² Administration of olomoucine (3 mg/kg/day) to rats after SCI significantly suppressed microglial proliferation and proinflammatory cytokine expression, reduced tissue edema formation, and attenuated the number of apoptotic neurons.²

References

1. Abraham, R.T., Acquarone, M., Andersen, A., *et al.* Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. *Biology of the Cell* **83**(2), 105-120 (1995).
2. Tian, D.-S., Xie, M.-J., Yu, Z.-Y., *et al.* Cell cycle inhibition attenuates microglia induced inflammatory response and alleviates neuronal cell death after spinal cord injury in rats. *Brain Res.* **1135**, 177-185 (2007).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/03/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM